arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ALNYLAM PHARMACEUTICALS, INC.

ALNY
$219.15 ▲ +2.69 (+1.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ALNYLAM PHARMACEUTICALS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $29.3B
Dividend Yield
Revenue Growth 66.9%
Op. Margin 17.9%
ROIC 15.8%
FCF / Share None
Trailing P/E 178.2x
Price / Book 21.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.29B
↑ +66.9%
Net Income Profit after all expenses
$205.99M
↑ +10.5%
Operating Margin Operating profit as % of sales
17.9%
↑ +49.3% 64th
FCF / Share Free cash flow per share
$2.58
↑ +362.7%
Long-Term Debt Long-term obligations
$677.72M
— +0.1%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
64
Returns
95
Financial Health
61
Cash Quality
79

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters